Alnylam Pharmaceuticals, Inc.
NASDAQAlnylam Pharmaceuticals enters the week with its most bullish options configuration of the past year, even as the short-side rebuild that defined early June quietly goes into reverse. The standout this week is in the options market. The put/call ratio has collapsed to 0.35 — the lowest reading in the past 52 weeks, against a 52-week high of 1.22 — and sits nearly 3.6 standard…
Snapshot as of 5 Jul 2026
Alnylam Pharmaceuticals enters the week with its most bullish options configuration of the past year, even as the short-side rebuild that defined early June quietly goes into reverse. The standout this week is in the…
Alnylam Pharmaceuticals enters June with a fresh tension: short sellers are quietly rebuilding positions in a stock the analyst consensus still rates a Buy — but where the share price sits $160 below the average Street…
Alnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year. The put/call ratio dropped to 0.39 on May 19, three standard…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALNY — free to start on ORTEX.
Sign up for free →Open ALNY on ORTEX